Børresen-Dale AL - Search Results

1

AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.

Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS. Kalous O, et al. Breast Cancer Res Treat. 2013 Oct;141(3):397-408. doi: 10.1007/s10549-013-2702-z. Epub 2013 Oct 5. Breast Cancer Res Treat. 2013. PMID: 24091768

2

p53 polymorphism and risk of cervical cancer.

Helland A, Langerød A, Johnsen H, Olsen AO, Skovlund E, Børresen-Dale AL. Helland A, et al. Nature. 1998 Dec 10;396(6711):530-1; author reply 532. doi: 10.1038/25034. Nature. 1998. PMID: 9859987 No abstract available.

3

BRCA1 screening in patients with a family history of breast or ovarian cancer.

Arver B, Claro A, Langerød A, Børresen-Dale AL, Lindblom A. Arver B, et al. Genet Test. 1999;3(2):223-6. doi: 10.1089/gte.1999.3.223. Genet Test. 1999. PMID: 10464672

4

The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.

Langerød A, Bukholm IR, Bregård A, Lønning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Børresen-Dale AL. Langerød A, et al. Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1684-8. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12496062

5

BUB1 infrequently mutated in human breast carcinomas.

Langerød A, Strømberg M, Chin K, Kristensen VN, Børresen-Dale AL. Langerød A, et al. Hum Mutat. 2003 Nov;22(5):420. doi: 10.1002/humu.9194. Hum Mutat. 2003. PMID: 14517964

6

Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications.

Kristensen VN, Sørlie T, Geisler J, Langerød A, Yoshimura N, Kåresen R, Harada N, Lønning PE, Børresen-Dale AL. Kristensen VN, et al. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):878s-83s. Clin Cancer Res. 2005. PMID: 15701881 Review.

7

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL. Olivier M, et al. Clin Cancer Res. 2006 Feb 15;12(4):1157-67. doi: 10.1158/1078-0432.CCR-05-1029. Clin Cancer Res. 2006. PMID: 16489069

8

Discovery and validation of breast cancer subtypes.

Kapp AV, Jeffrey SS, Langerød A, Børresen-Dale AL, Han W, Noh DY, Bukholm IR, Nicolau M, Brown PO, Tibshirani R. Kapp AV, et al. BMC Genomics. 2006 Sep 11;7:231. doi: 10.1186/1471-2164-7-231. BMC Genomics. 2006. PMID: 16965636 Free PMC article.

9

Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.

Baumbusch LO, Myhre S, Langerød A, Bergamaschi A, Geisler SB, Lønning PE, Deppert W, Dornreiter I, Børresen-Dale AL. Baumbusch LO, et al. Mol Cancer. 2006 Oct 20;5:47. doi: 10.1186/1476-4598-5-47. Mol Cancer. 2006. PMID: 17054774 Free PMC article.

10

Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas.

Chanock SJ, Burdett L, Yeager M, Llaca V, Langerød A, Presswalla S, Kaaresen R, Strausberg RL, Gerhard DS, Kristensen V, Perou CM, Børresen-Dale AL. Chanock SJ, et al. Breast Cancer Res. 2007;9(1):R5. doi: 10.1186/bcr1637. Breast Cancer Res. 2007. PMID: 17224074 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

511 results

Search Page

Filters